ARRANON

Orphan Drug Designations

The following drugs have received orphan drug designation from the FDA for lymphoblastic lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Gene therapy approaches for lymphoblastic lymphoma have been reported in the published literature.

297 publications have been identified in PubMed for lymphoblastic lymphoma. Kisho has analyzed 165 by research type. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (20%), and Clinical Trial Publication (12%).

Recent Publications

• Liu Z (2026). [PMID: 41618586](https://pubmed.ncbi.nlm.nih.gov/41618586/). *Pediatr Blood Cancer*. [Diagnostic / Biomarker]

• Zhang H (2026). [PMID: 40736563](https://pubmed.ncbi.nlm.nih.gov/40736563/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]

• Cui W (2026). [PMID: 41021397](https://pubmed.ncbi.nlm.nih.gov/41021397/). *Acta Cytol*. [Basic Science / Preclinical]

• Bosch-Schips J (2026). [PMID: 41611915](https://pubmed.ncbi.nlm.nih.gov/41611915/). *Pathologie (Heidelb)*. [Review / Meta-Analysis]

• Di Giacomo D (2026). [PMID: 41791840](https://pubmed.ncbi.nlm.nih.gov/41791840/). *Blood*. [Basic Science / Preclinical]

• Leijnen F (2026). [PMID: 41752218](https://pubmed.ncbi.nlm.nih.gov/41752218/). *Int J Mol Sci*. [Review / Meta-Analysis]

• Bian W (2026). [PMID: 41824879](https://pubmed.ncbi.nlm.nih.gov/41824879/). *Medicine (Baltimore)*. [Review / Meta-Analysis]

• Matijasic Stjepovic N (2026). [PMID: 41835666](https://pubmed.ncbi.nlm.nih.gov/41835666/). *Cureus*. [Epidemiology / Natural History]

• Guo W (2026). [PMID: 41299066](https://pubmed.ncbi.nlm.nih.gov/41299066/). *Oncogene*. [Clinical Trial Publication]

• Selim C (2026). [PMID: 42232536](https://pubmed.ncbi.nlm.nih.gov/42232536/). *Front Oncol*. [Epidemiology / Natural History]